InnoSer and Inficure Bio enter partnership to increase accessibility of translational liver inflammation & fibrosis mouse model Read the entire pressrelease here!
About wpadminThis author has not yet filled in any details.
So far wpadmin has created 61 blog entries.
The Umeå based life science company InfiCure Bio continues to take large steps in the global market by signing agreements with two major international companies. “The contracts with our new clients clearly show that pharmaceutical companies continue to invest in the development of new drugs for fibrosis, which is extremely promising for InfiCure Bio”, says [...]
Sofia Mayans, CEO at Inficure Bio, will attend the annual Nordic Life Science Days in Malmö 28-29 September. We hope that you will meet Sofia in Malmö for fruitful discussions!
InfiCure attended the EASL NAFLD summit digitally, please take the opportunity to read our poster "Effects of high fat diet on development of NASH in the NIF mouse model". The poster can be found here.
InfiCure Bio presented the poster "NKT cells promote both type 1 and type 2 inflammatory responses in the non-obese diabetic inflammation and fibrosis (NIF) mouse model". You will find the poster here.
InfiCure Bio will attend the yearly EASL meeting with a poster, please take the opportunity to check out poster #FRI-154 "NKT cells promote both type 1 and type 2 inflammatory responses in the non-obese diabetic inflammation and fibrosis (NIF) mouse model".
Today on May 3rd, Umeå Biotech Incubator (UBI) organized the first Umeå Life Science Job Fair. We at InfiCure Bio were happy to get the opportunity to present our business to life science students and potential future job applicants. In spite of a quite cold and windy day, the event was very popular and we [...]
Take the opportunity to read the pressrelease on the CymaBay study with Seladelpar in the NIF mouse. Ed Cable, sr. Director of Research at CymaBay Therapeutics, gives his view on why CymaBay chose to work with the NIF mouse, and comments on the positive results. You will find the full pressrelease here.
We are very happy that CymaBay Therapeutics chose to present the convincing data from their study in the NIF mouse. They nicely show that Seladelpar, which is a substance in clinical studies, reduces fibrosis in the NIF mouse in both liver and kidney. You will find the PDF of the poster "Seladelpar reduces established liver [...]